

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/021,126	
			Filing Date	December 12, 2001	
			First Named Inventor	Connie Sanchez	
			Art Unit	1614	
			Examiner Name	F. Krass	
Sheet	1	of	1	Attorney Docket Number	05432/000J951-US0

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁴ -Kind Code ⁵ (if known)				
SUS	1	EP-0474580	03-11-1992	H Lundbeck A/S		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
SUS	2	Hytell, J., Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 1982, 6, 277-295		
	3	Gravem, A., Acta Psychiatr. Scand., 1987, 75, 478-486		
	4	Sanchez, C., Effect of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats, Behav. Pharmacol. 1993; 4:267-277		
	5	Sanchez, C., Pharmacol. Toxicol. 77, 71-78 (1995)		
	6	Sanchez, C., R-citaloram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model, European Journal of Pharmacology, 464, 2003, pp. 155-158		
	7	Montgomery, S., et al., Escitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted from a Rat Model, Pharmacology & Toxicology, 2001, 88, 282-286		
	8	Sanchez, C., Stress-induced vocalisation in adult animals: A valid model of anxiety?, European Journal of Pharmacology, 463 (2003) 133-143		
	9	Burke, W., et al., Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients, J. Clin Psychiatry, 63:4, April 2002		
	10	Wade, A., et al., Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care, International Clinical Psychopharmacology 2002, Vol. 17, No. 3		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

W:1054 321000	<i>[Signature]</i>	Date Considered	9/14/05
------------------	--------------------	--------------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/021,126-Conf. #7268
				Filing Date	December 12, 2001
				First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	F. Krass
				Attorney Docket Number	05432/000J951-US0
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SVS	1	Stahl et al., J. Clin. Psychiatry 2003; 64:1322-1327.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

9/14/05

(W:1054 3210001		Date Considered	9/14/05
--------------------	--	--------------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/021,126-Conf. #7268
				Filing Date	December 12, 2001
				First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	F. F. Krass
Sheet	1	of	2	Attorney Docket Number	05432/000J951-USO


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
SJS	1	US-2002/0103249-A1	08-01-2002	H. Lundbeck A/S	
	2	US- 6,169,105-B1	01-2001	Wong et al.	
	3	US- 6,184,219-B1	02-2001	Evenden et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁵ -Kind Code ⁶ (if known)	MM-DD-YYYY			
SJS	4	EP-0 347 066 A1	12-20-1989	H. Lundbeck A/S		
	5	WO-01/03694 A1	01-18-2001	H. Lundbeck A/S		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
SJS	6	Sackeim, H.A., The definition and meaning of treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 10-17			
	7	Willner, P., Psychopharmacology, 1997, 134, 319-329			
	8	Nierenber, A.A and DeCecco, L.M., Definitions of antidepressant treatment response, remission, non-response, partial response, and other relevant outcomes: A focus on treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 5-9			
	9	Kornstein, S.C. and Schneider, R.K., Clinical features of treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 18-25			
	10	Poster, "Escitalopram and Paroxetine in Fixed Doses for the Treatment of Social Anxiety Disorder (SAD), Presented at the 44th Annual Meeting of the Scandinavian College of Neuro-Psychopharmacology, 9-12 April 2003, Juan-les-Pins, France, 1 page.			
	11	Kasper, Siegfried, et al., "Escitalopram is Efficacious and well Tolerated in Treatment of Social Anxiety Disorder", ADAA National Conference, 21-24 March 2002, 1 page.			
	12	Davidson, Jonathan, et al., "Escitalopram in the Treatment of Generalized Anxiety Disorder", Presented at the 22nd National Conference of the Anxiety Disorder Association of America, March 21-24, 2002, Austin, Texas, NR57, 1 page.			
	13	Stahl, Stephen, et al., "Escitalopram in the Treatment of Panic Disorder", Presented at the 22nd National Conference of the Anxiety Disorders Association of America, March 21-24, 2002, Austin, Texas, NR56, 1 page.			
	14	Lader, Malcolm, et al., "Efficacy and Tolerability of Escitalopram in 12- and 24-Week Treatment of Social Anxiety Disorder: Randomised, Double-Blind, Placebo-Controlled, Fixed-Dose Study", Depression and Anxiety, 19: 241-248 (2004).			
	15	Huffman, Jeff C., et al., "The Development of New Antidepressants: Focus on Duloxetine and Escitalopram", Harv Rev Psychiatry, 11:30-36 (2003).			
	16	Waugh, John, et al., "Escitalopram, A review of its Use in the Management of Major			

Examiner Signature		Date Considered	9/19/05
-----------------------	--	--------------------	---------



Substitute for form 1449A/B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/021,126-Conf. #7268		
		Filing Date	December 12, 2001		
		First Named Inventor	Connie Sanchez		
		Art Unit	1614		
		Examiner Name	F. F. Krass		
Sheet	2	of	2	Attorney Docket Number	05432/000J951-US0

17	Depressive and Anxiety Disorders", CNS Drugs, 17 (5): 343-362 (2003).
18	Burke, William J., "Escitalopram", Expert Opin. Investig. Drugs, 11(10): 1477-1486 (2002).
19	Farah, Andrew, "Therapeutic Advantages of Escitalopram in Depression and Anxiety Disorders", Primary Psychiatry, 9(12): 30-35 (2002).
20	Montgomery, S.A., et al., "The antidepressant efficacy of citalopram", International Clinical Psychopharmacology (1996), Vol. 11, Supplement 1, pp. 29-33.
	Bouchard, J.M., et al., "Citalopram and Viloxazine in the treatment of depression by means of slow drop infusion: A double-blind comparative trial", Journal of Affective Disorders, Vol. 46, pp. 51-58 (1997).


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

[Handwritten signature]

9/14/05

Examiner Signature	<i>[Handwritten signature]</i>	Date Considered	9/14/05
--------------------	--------------------------------	-----------------	---------



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/021,126-Conf. #7268
				Filing Date	December 12, 2001
				First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	F. Krass
Sheet	1	of	1	Attorney Docket Number	05432/000J951-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
SK	CA /	P. Auquier et al., <i>Int. J. Psychiatr. Clin. Pract.</i> 7:259-268 (2003) .			
	CB /	E. Bien et al., <i>Behav. Pharmacol.</i> 14:S37 (2003).			
	CC	E. W. Fish et al., <i>J. Pharmacol. Exp. Ther.</i> October 30, 2003, Fast Forward publ. as DOI: 10.1124/jpet.103.058206 (2004).			
	CD	C. Sanchez et al., <i>Psychopharmacology</i> 167:353-362 (2003) .			
	CE /	C. Sanchez, <i>Behav. Pharmacol.</i> 14:465-470 (2003) .			
	CF /	C. Sanchez et al. <i>Psychopharmacology (Berl.)</i> (2004), "Escitalopram versus citalopram: the surprising role of the R-enantiomer".			
	CG /	Declaration of Connie Sanchez.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The PTO did not receive the following
listed item(s) cite # CC

W:1054 321000		Date Considered	9/14/05
------------------	--	--------------------	---------



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/021,126-Conf. #7268
				Filing Date	December 12, 2001
				First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	F. Krass
Sheet	1	of	1	Attorney Docket Number	05432/000J951-US0

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
SUS	CA ✓	P. Auquier et al., <i>Int. J. Psychiatr. Clin. Pract.</i> 7:259-268 (2003) .			
	CB ✓	E. Bien et al., <i>Behav. Pharmacol.</i> 14:S37 (2003).			
	CC	E. W. Fish et al., <i>J. Pharmacol. Exp. Ther.</i> October 30, 2003, Fast Forward publ. as DOI: 10.1124/jpet.103.058206 (2004).			
	CD	C. Sanchez et al., <i>Physchopharmacology</i> 167:353-362 (2003) .			
	CE ✓	C. Sanchez, <i>Behav. Pharmacol.</i> 14:465-470 (2003) .			
	CF ✓	C. Sanchez et al. <i>Phychopharmacology (Berl.)</i> (2004), "Escitalopram versus citalopram: the surprising role of the R-enantiomer".			
	CG	Declaration of Connie Sanchez.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The PTO did not receive the following
listed item(s) cite # CC

W:1054 3210001		Date Considered	9/27/05
-------------------	--	--------------------	---------



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/P TO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/021,126-Conf.#7268		
		Filing Date	December 12, 2001		
		First Named Inventor	Connie Sanchez		
		Art Unit	1614		
		Examiner Name	F. F. Krass		
Sheet	1	of	1	Attorney Docket Number	05432/000J951-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
SUS	AA	US-5,627,196-B1	05-06-1997	Hibschman et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
4/3	BA	WO-99/14207-A1		03-25-1999	Berg Stefan		
	BB	EP-0 814 084-A1		12-29-1997	Eli Lilly Co.		
	BC	WO-96/24353-A1		08-15-1996	Eli Lilly Co.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SUS	CA	Hyttel, J., et al., "The pharmacological effect of citalopram residues in the (S) - (+)-enantiomer", Journal of Neural Transmission, 1992, Vol. 88, no. 2, pp. 157-160.	
	CB	Sanchez, Connie, et al., "Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression", Psychopharmacology, 1997, Vol. 129, pp. 197-205.	
	CC	Lepola U., et al., "Citalopram in the Treatment of Social Phobia: A Report of Three Cases", Pharmacopsychiatry, September 1994, Vol. 27, no. 5, pp. 186-188.	
	CD	Humble, M., et al., "Serotonin, Panic Disorder and Agoraphobia: Short-Term and Long-Term Efficacy of Citalopram in Panic Disorders", International Clinical Psychopharmacology, 1992, Vol. 6, no. suppl 5, pp. 21-39.	
	CE	Bouwer, C., et al., "Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia", Journal of Affective Disorders, April 1998, vol. 49, no. 1, pp. 79-82.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	9/14/05
-----------------------	--	--------------------	---------